TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01722708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Oral clindamycin 300 Milligrams\*2/Day for a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Oral metronidazole 500 Milligrams\*2/Day for a week
Study: NCT04540419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study: NCT03047187

Intervention type: DIAGNOSTIC_TEST
Intervention: ACLR
Description: * quadriceps and hamstring isometric muscles test~* single hop for distance~* IKDC, KOOS, Tampa and ACL-RSI Questionnaires
Study: NCT04383548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin
Description: Prospective randomized clinical study for efficacy of anti-SARS-CoV-2 hyper immunoglobulins prepared from COVID19 convalescent plasma using VIPS Mini-Pool IVIG medical device
Study: NCT00584324

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BIS 40
Description: Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BIS 40
Description: Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BIS 60
Description: Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BIS 60
Description: Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure.
Study: NCT00555620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
Study: NCT05268653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivatıonal İnterviewing (Treatment Group)
Description: Obese adolescents will be given a 6-session motivational interview.
Study: NCT01510951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 811 or Placebo
Description: Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 811 or Placebo
Description: Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
Study: NCT03618251

Intervention type: DIAGNOSTIC_TEST
Intervention: specific MRI sequences
Description: MRI with B 2000 of diffusion weighted imaging and the coefficient of apparent diffusion
Study: NCT03751176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
Study: NCT00858494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyland's Cold 'n Cough 4 Kids
Description: Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
Study: NCT04081779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive telephone-based educational counseling session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02316418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hairstetics™ anchoring system
Description: Overall, up to 360 prosthetic hair implants will be set in the scalp. The procedure will be performed in accordance with the instructions in the device Instructions for Use. Training and certification of operators by the Sponsor is a prerequisite for use of the study device by the former.~Hair extensions will be attached to the fibers four weeks after the implantation.
Study: NCT04308941

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular pressure
Description: The intraocular pressure will be measured using one of three devices

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular pressure
Description: The intraocular pressure will be measured using one of three devices

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular pressure
Description: The intraocular pressure will be measured using one of three devices
Study: NCT03161561

Intervention type: OTHER
Group type: OTHER
Intervention: capacity of primary phagocytes
Description: measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
Study: NCT03561974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humidification
Description: Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
Study: NCT01536496

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood product transfusion based on conventional coagulation tests.
Description: Transfusion of blood products.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood product transfusion based on rapid thrombelastography (r-TEG) results.
Description: Transfusion of blood products.
Study: NCT01191710

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In vitro fertilization
Description: In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vitro fertilization
Description: In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
Study: NCT01748786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Emotion Regulation
Description: 12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: 12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
Study: NCT01861626

Intervention type: DRUG
Group type: OTHER
Intervention: V0057 - A mg
Description: Single oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: V0057 - A mg
Description: Single oral administration
Study: NCT03646721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1241
Description: \[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)
Study: NCT01861626

Intervention type: DRUG
Group type: OTHER
Intervention: Isotretinoin
Description: Single oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Isotretinoin
Description: Single oral administration
Study: NCT03391934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + FOLFIRI
Description: Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
Study: NCT03646721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1241
Description: \[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: \[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: \[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: \[Part2\] Administration of Sitagliptin 100mg once daily for 56 days.
Study: NCT03391934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + FOLFIRI
Description: Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
Study: NCT00207311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenical, Pegasys, Copegus
Description: Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Xenicare Program
Description: Xenicare program for 36 weeks.
Study: NCT02524171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moral Reconation Therapy (MRT)
Description: MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
Study: NCT03133507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reapprasial Condition
Description: Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reassurance Condition
Description: Children will be reassured by the experimenter .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction Condition
Description: Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
Study: NCT00704886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: video of dementia
Study: NCT02781675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 3 wk dietary intervention with prescribed menus and \~50% foods provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 3 wk dietary intervention with prescribed menus and \~50% foods provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 3 wk dietary intervention with prescribed menus and \~50% foods provided.
Study: NCT02535455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACES Pilot
Description: This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
Study: NCT03771092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SunActive®Fe
Description: SunActive® Fe is a colorless, odorless, tasteless iron fortifier in a powder form. This product is most commonly used to increase the amount of iron in food, beverage, and dietary supplement applications.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SunActive®Fe
Description: SunActive® Fe is a colorless, odorless, tasteless iron fortifier in a powder form. This product is most commonly used to increase the amount of iron in food, beverage, and dietary supplement applications.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipofer®
Description: Lipofer® is a micronized and microencapsulated source of iron, enhances the bioavailability of iron and does not taste metallic or oxidize unsaturated fats.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipofer®
Description: Lipofer® is a micronized and microencapsulated source of iron, enhances the bioavailability of iron and does not taste metallic or oxidize unsaturated fats.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intravenous ferric gluconate
Description: Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 - 440,000 daltons on gel chromatography. It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate.
Study: NCT01941615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir
Description: oral doses for 10 days (period B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: oral doses for 23 days (period A+B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: oral doses for 10 days (period B)
Study: NCT00047450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram (Celexa)
Description: Citalopram for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 months
Study: NCT01944059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theramine (medical food/old drug)
Description: Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (l-alanine)
Description: Theramine like placebo comparator
Study: NCT03645629

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin test with food at different storage times
Description: Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin test with food at different storage times
Description: Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin test with food at different storage times
Description: Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
Study: NCT02477644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets, per os, 300 mg twice daily;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, per os, 300 mg twice daily.
Study: NCT00477880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT03766295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03613207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermal pharmacokinetic measurement
Description: * Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~* Each test site receives 2 dOFM probes~* Dosing:~  * 2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~ * 2 test sites: untreated test site~* ISF sampling: 24 hours post-dose~* Blood sampling: 7 samples post-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine and prilocaine cream
Description: lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
Study: NCT02545582

Intervention type: DEVICE
Intervention: VITARIA System
Description: Implantable vagus nerve stimulator
Study: NCT03829605

Intervention type: OTHER
Intervention: Measurement of hydrogen sulfide
Description: Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia

Intervention type: OTHER
Intervention: Measurement of hydrogen sulfide
Description: Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia
Study: NCT03209271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's Acetate (warm)
Description: Body temperature fluid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Acetate (cold)
Description: Room temperature fluid
Study: NCT01629511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo stem cell transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study: NCT03715335

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted STI Screening
Description: GC/CT screening will be offered to those who screen at risk or at high risk for STIs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universally Offered STI Screening
Description: GC/CT screening will be offered to all patients who meet the age eligibility criteria.
Study: NCT04522271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: 7.5 g resistant starch/m2 oral consumption

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral consumption of food-grade cornstarch
Study: NCT01683331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin treatment for hyperglycemia
Study: NCT03715816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work break schedule
Description: Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work break schedule
Description: Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
Study: NCT01629511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO